AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT05654844 — intervention group
Intervention type: RADIATION
Group type: OTHER
Intervention: LC images
Description: Angular and Linear Measurements were compared in mandibular symphysis region using the LC images
Study NCT05654844 — intervention group
Intervention type: RADIATION
Group type: OTHER
Intervention: CBCT images
Description: Angular and Linear Measurements were compared in mandibular symphysis region using the CBCT images
Study NCT01872728 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Bilateral facial block after general anesthesia before surgery
Description: Bilateral facial block (infraorbital and infratrochlear) after general anesthesia before surgery with intravenous placebo or bilateral block with placebo and intravenous morphine
Study NCT01872728 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Bilateral facial block after general anesthesia before surgery
Description: Bilateral facial block (infraorbital and infratrochlear) after general anesthesia before surgery with intravenous placebo or bilateral block with placebo and intravenous morphine
Study NCT04381390 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Whole egg and resistance training
Description: This intervention consisted of whole egg consumption concomitant with 12 weeks of resistance training. Subject ingested three whole eggs per day immediately after resistance training.
Study NCT04381390 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Egg whites and resistance training
Description: This intervention consisted of egg white consumption concomitant with 12 weeks of resistance training. Subject ingested an isonitrogenous quantity of six egg whites per day immediately after resistance training.
Study NCT00713700 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: AMPLATZER Duct Occluder II
Description: AMPLATZER Duct Occluder II
Study NCT03496909 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Standard OT
Description: 12 weekly sessions of occupational therapy tailored to patients with RFS secondary to breast cancer treatment. Sessions can include manual therapy, education, and active and passive range-of-motion, etc.
Study NCT03496909 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: PhysioTouch
Description: 12 weekly sessions of occupational therapy tailored to patients with RFS secondary to breast cancer treatment. Sessions can include use of the PhysioTouch electronic massager in lieu of manual therapy, education, and active and passive range-of-motion, etc.
Study NCT04358679 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Conventional Treatment
Description: Conventional Treatment:~* Deep breathing: 10-15 reps, twice a day (BD)~* Assisted coughing 10-15 reps, BD~* range of motion (ROM)+ stretching 10 reps, BD~* Tilt table standing
Study NCT04358679 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Upper Limb ergometer training
Description: Conventional Treatment + upper limb (UL) ergometry exercise UL ergometry exercise 15 to 20 mints , 2 times ,five days per week for 6 weeks.
Study NCT03790683 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: EnsoETM
Description: Patients having major surgery will have the EnsoETM device placed after induction of general anesthesia. Addition of standard of care surface warming was specified as optional after first 7 patients.
Study NCT03790683 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Surface Warming
Description: Forced air warming device will be placed on the patient according to standard practice.
Study NCT03790683 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Surface Warming
Description: Forced air warming device will be placed on the patient according to standard practice.
Study NCT04803838 — intervention group
Intervention type: OTHER
Intervention: No intervention
Description: No intervention
Study NCT03628170 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: platelet rich fibrin
Description: platelet rich fibrin will be prepared from patient's venous blood and inserted in the centrifuge at 2000 r.p.m. for 12 minutes Then, the Platelet rich fibrin plug will be placed in the socket after extraction for socket preservation covered by platelet rich fibrin membrane.
Study NCT03628170 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Free gingival graft
Description: Free gingival graft will be taken from the palate to cover the socket after extraction of the tooth for socket preservation.
Study NCT04607083 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: Polyp carachterization by combing endoscopist evaluation and Ai output
Description: A polyp characterization (adenoma vs. non adenoma) is provided by endoscopist in light of the results of this own evaluation and of the Ai system output. The confidence level (high vs. low) in polyp characterization is recorded. The combined evaluation is compared with histopathology results.
Study NCT03799029 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Cognitive training
Description: Participants will train at home during 25 sessions (about 45 minutes each) over a maximum of 5 weeks. Investigators will verify compliance via Internet and call participants and their legal guardians once a week. A reward system will be established with participants. Five sessions of metacognition (1 hour each) are added.
Study NCT01678144 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Mitral valve repair using the Medtentia Annuloplasty Ring (MAR)
Study NCT02631200 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Advance care plan
Description: Participants will be offered the opportunity to complete an ACP by a nurse trained as an ACP facilitator, who will discuss the process with them using standard materials. At least 48 hours later, they will complete an ACP document with the help of the ACP facilitator, working together with trained expert patients who will provide peer support at the time of ACP completion and subsequently by telephone, assisted where necessary by the ACP facilitator.
Study NCT03124784 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: RD Disposable Sensors
Description: Noninvasive pulse oximeter sensor
Study NCT01778114 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Vitamin D2 in orange juice
Description: 1000 IU dose
Study NCT01778114 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Vitamin D3 in orange juice
Description: 1000 IU
Study NCT01778114 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Vitamin D2
Description: capsule, 1000 IU
Study NCT01778114 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Vitamin D3
Description: capsule, 1000 IU
Study NCT01778114 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo
Study NCT03372031 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Piano training (Active)
Description: Piano Curriculum. Participants were all trained on one of four 88-key pianos located in the assisted living facility. Piano instructors were 6 undergraduate Music Education and Music Performance majors. Each lesson of the week had a different focus: right and left hands separately, bimanually coupled, and bimanually uncoupled (Loehrer et al., 2016). Each week of the module had a different focus as well: notes played one step apart, notes played multiple steps apart (intervals), and tones played together (two-note chords) (van Vugt et al., 2016; Villeneuve et al., 2014). Each session began with skill exercises and ended with learning a simple, recognizable song. Two participants with extensive piano experience progressed to playing duets with the instructor and hymns out of a hymnal after mastery of the study curriculum. These training protocols were based on those of Schneider and colleagues' 2007 study.
Study NCT03372031 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Piano Training (Passive)
Description: Participants listened to their research partner complete 8 active piano training sessions across 2 weeks.
Study NCT03027752 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Operation carotid endarterectomy with plastic of xenopericardial patch
Description: Under local anesthesia Sol.Novocaini 0.25%, wires or endotracheal anesthesia using the standard access the bifurcation of the common carotid artery, internal carotid artery, isolated on identical distance external carotid artery. Common carotid artery cut then performed a longitudinal arteriotomy on the front of the anterior surface of the internal carotid artery. Under the visual control performs a sequence of endarterectomy of the internal carotid artery. Plastic arteriotomy performed patche of ksenoperikardial (Kemperiplas-Neo) treated with epoxy compounds.
Study NCT03027752 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: New method of operation сarotid endarterectomy with autoarterial remodeling of bifurcation CCA
Description: Under local anesthesia Sol.Novocaini 0.25%, or endotracheal anesthesia using the standard access the bifurcation of the common carotid artery, internal carotid artery, isolated on identical distance external carotid artery. Carotid glomus separated and moves downward and backward bifurcation of the common carotid artery. External carotid artery is cut off at an angle of 45º from the mouth with a portion of the common carotid artery, then performed a longitudinal arteriotomy on the front of the medial surface of the internal carotid and posterior-lateral surface of the external carotid artery. Under the visual control performs a sequence of endarterectomy of the internal and external carotid arteries. The final recovery of the arteries is performed by crosslinking of their walls with each other in a side by side type between the internal and external carotid arteries 6/0 Polypropylene thread with two needles.
Study NCT02322060 — intervention group
Intervention type: PROCEDURE
Intervention: Ovariotomy
Description: Remove one ovary (maybe both ovaries depending on the condition) by laparoscopic surgery or by laparotomy in some cases.
Study NCT02322060 — intervention group
Intervention type: PROCEDURE
Intervention: Activate dormant follicles
Description: Cut ovary into small cubes, which are then cultured with medium containing BPV(pic), a PTEN inhibitor, and 740YP, an activator of phosphoinositol 3 kinase, to activate dormant follicles for 2 days before transplantation.
Study NCT02322060 — intervention group
Intervention type: PROCEDURE
Intervention: Ovary tissue transplantation
Description: After extensive washing to remove drugs, the ovary cubes are transplanted beneath the membrane of both Fallopian tubes and the remaining ovary under laparoscopic surgery.
Study NCT02322060 — intervention group
Intervention type: PROCEDURE
Intervention: Ovarian superficial cut
Description: Superficial cut of the ovarian cortex by laparoscopy or laparotomy
Study NCT03185390 — intervention group
Intervention type: PROCEDURE
Group type: OTHER
Intervention: ERCP guided biopsy or brush cytology
Description: ERCP guided biopsy or brush cytology
Study NCT00711100 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Camel Snus
Description: All subjects will sample Camel Snus and determine if they would prefer to use this product during the abstinence phase over the other products sampled. Sampling period (duration: 1/2 day) requires use of at least 3 samples of Camel Snus. Intervention period (duration: 2 weeks) involves ad libitum daily use (if Camel Snus is chosen for use) during abstinence phase.
Study NCT00711100 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Marlboro Snus
Description: All subjects will sample Marlboro Snus and determine if they would prefer to use this product during the abstinence phase over the other products sampled. Sampling period (duration: 1/2 day) requires use of at least 3 samples of Marlboro Snus. Intervention period (duration: 2 weeks) involves ad libitum daily use (if Marlboro Snus is chosen for use) during abstinence phase.
Study NCT00711100 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Stonewall
Description: All subjects will sample Stonewall and determine if they would prefer to use this product during the abstinence phase over the other products sampled. Sampling period (duration: 1/2 day) requires use of at least 3 samples of Stonewall. Intervention period (duration: 2 weeks) involves ad libitum daily use (if Stonewall is chosen for use) during abstinence phase.
Study NCT00711100 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Ariva
Description: All subjects will sample Ariva and determine if they would prefer to use this product during the abstinence phase over the other products sampled. Sampling period (duration: 1/2 day) requires use of at least 3 samples of Ariva. Intervention period (duration: 2 weeks) involves ad libitum daily use (if Ariva is chosen for use) during abstinence phase.
Study NCT00711100 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: General Snus
Description: All subjects will sample General Snus and determine if they would prefer to use this product during the abstinence phase over the other products sampled. Sampling period (duration: 1/2 day) requires use of at least 3 samples of General Snus. Intervention period (duration: 2 weeks) involves ad libitum daily use (if General Snus is chosen for use) during abstinence phase.
Study NCT02022982 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Palbociclib
Description: Palbociclib will be administered orally once daily, 3 weeks out of every 4 in each cycle. The initial dose for phase 1 of the study will be 75 mg daily. Dosing will be adjusted until Maximum Tolerated Dose (MTD) and the Recommended Phase 2 Dose (RP2D) are established. No pre-medications for palbociclib are required. It should be administered without food with patients fasting for 1 hour prior and 2 hours post drug administration.
Study NCT02022982 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PD-0325901
Description: PD-0325901 will be administered orally twice daily, 3 weeks out of every 4 in each cycle. The initial dose for phase 1 of the study will be 2 mg twice daily. Dosing will be adjusted until Maximum Tolerated Dose (MTD) and the Recommended Phase 2 Dose (RP2D) are established. PD-0325901 will be administered using a flat-dosing plan. No premedications are required. As the effect of food on PD-0325901 is uncertain, patients will be permitted to dose either fasting or after food.
Study NCT02458196 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Prednisone
Description: Prednisone: started with prednisone alone 0. 6-0. 8mg/kg.d for 1 month, decreased 5mg per 2 weeks, and maintained at 10mg/d to 12 months.
Study NCT02458196 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Prednisone and Mycophenolate mofetil
Description: Prednisone: started with prednisone 0. 6-0. 8mg/kg.d for 1 month, decreased 5mg per 2 weeks, maintained at 7.5mg to 10mg/d to 12 months.~Immunosuppressive drugs: Mycophenolate mofetil 1g/d-1.5g/d for 6 months and 0.5/d-1.0g/d for 6 months.
Study NCT02792842 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ART-123 (3-day ART)
Description: ART-123 380 U/kg infusion once daily on days 1-3 in each cycle
Study NCT02792842 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ART-123 (1-day ART)
Description: ART-123 380 U/kg infusion once on day 1 and placebo infusion once daily on days 2-3 in each cycle
Study NCT02792842 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo infusion once daily on days 1-3 in each cycle
Study NCT00777569 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nicotine free cigarettes
Description: Quest Step 2 contains 0.05 mg nicotine
Study NCT00777569 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Extra-low nicotine cigarettes
Description: Quest 2 cigarettes contains 0.3 mg nicotine
Study NCT00777569 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Nicotine Lozenge
Description: 4 mg nicotine lozenge
Study NCT04461990 — intervention group
Intervention type: PROCEDURE
Intervention: Multidisciplinary cooperative comprehensive treatment
Description: Local surgery, radiation therapy, and systemic therapy such as chemotherapy, endocrine and molecular targeting.
Study NCT02513329 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Bupivicaine
Description: A computer-generated 1:1 block randomization scheme will be used to assign participants to receive bupivacaine. Randomization will be performed by the injectionist immediately before the injection procedure by opening an opaque envelope to reveal the participant number and group assignment printed on an index card.10 mL .5% bupivicaine will be administered.
Study NCT02513329 — intervention group
Intervention type: DRUG
Group type: SHAM_COMPARATOR
Intervention: Saline
Description: A computer-generated 1:1 block randomization scheme will be used to assign participants to receive saline. Randomization will be performed by the injectionist immediately before the injection procedure by opening an opaque envelope to reveal the participant number and group assignment printed on an index card. 5 mL sterile normal saline will be administered.
Study NCT02672566 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Enoxaparin
Description: Enoxaparin will be delivered to the patients every day at the dose of 4 000 Ui.
Study NCT02672566 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Usual care
Description: Patients will all benefit from the usual care
Study NCT02672566 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Usual care
Description: Patients will all benefit from the usual care
Study NCT00539695 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: IL-2
Description: IL2 Administration:~Patients will be given a fixed dose (1x10e5 units/m2/dose) of IL-2 given as a subcutaneous injection three times weekly (separated by at least one day) for 6 weeks beginning no earlier than day +7 after HSCT but beginning no later than 30 days after HSCT. If the patient has not developed >grade I side effects to IL-2 and has not developed >grade I GVHD then the patient may continue the IL-2 for 6 additional weeks. Time will be measured as 'week beginning with first IL-2 injection.
Study NCT01365663 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SPC4955
Description: 3 Weekly SC injections
Study NCT01365663 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Saline 0.9%
Description: 3 Weekly SC injections
Study NCT01131000 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ibuprofen
Description: Intravenous ibuprofen, 100 mg, Single-dose
Study NCT01131000 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ibuprofen
Description: Intravenous ibuprofen, 200mg, single dose
Study NCT01131000 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ibuprofen
Description: Intravenous ibuprofen, 400 mg, Single-dose
Study NCT01131000 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Normal Saline
Description: Normal Saline, 100 ml, Single-dose
Study NCT01702610 — intervention group
Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: IMRT Technique
Study NCT01702610 — intervention group
Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: IMRT and accelerated hypofractionation technique
Description: Intervention is the technique and accelerated fractionation used to treat GBM
Study NCT01702610 — intervention group
Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: neo-adjuvant TMZ followed by accelerated hypofractionated EBRT
Description: Two weeks of neo-adjuvant TMZ followed by XRT+TMX followed by TMZ as adjuvant component
Study NCT01702610 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Temozolomide and Accelerated Hypofractionation RT
Study NCT04163445 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: MicroPort Orthopedics EVOLUTION Medial Pivot TKA
Description: Subjects will have been implanted with the Microport Evolution Medial Pivot TKA
Study NCT04163445 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Depuy Synthes ATTUNE PCR TKA
Description: Subjects will have been implanted with the Depuy Attune PCR TKA
Study NCT02490514 — intervention group
Intervention type: OTHER
Intervention: No intervention
Description: No intervention was administered in this study.
Study NCT01340209 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tiotropium Respimat
Description: Tiotropium high dose once daily delivered with Respimat inhaler
Study NCT01340209 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo Respimat
Description: Tiotropium placebo once daily delivered with Respimat inhaler
Study NCT01340209 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tiotropium Respimat
Description: Tiotropium low dose once daily delivered with Respimat inhaler
Study NCT01571115 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Physical Exercise
Study NCT05287009 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: ILM nonpeeling
Description: ILM is not peeled after ERM removal
Study NCT05287009 — intervention group
Intervention type: PROCEDURE
Group type: OTHER
Intervention: ILM peeling
Description: ILM is peeled after ERM removal
Study NCT02824744 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: treatment by 2l/min/kg in High Flow Nasal cannula (HFNC)
Study NCT02824744 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: treatment by 3l/min/kg in High Flow Nasal cannula (HFNC)
Study NCT01294800 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Preladenant
Description: 2, 5, or 10 mg tablets taken orally twice daily (BID)
Study NCT01294800 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo tablet to match Preladenant
Description: tablets taken orally BID
Study NCT02268058 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Acetaminophen
Description: routine administration of medication for a 72 hour period
Study NCT02268058 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Ibuprofen
Description: routine administration of medication for a 72 hour period